Your browser doesn't support javascript.
loading
IMWG consensus on risk stratification in multiple myeloma.
Chng, W J; Dispenzieri, A; Chim, C-S; Fonseca, R; Goldschmidt, H; Lentzsch, S; Munshi, N; Palumbo, A; Miguel, J S; Sonneveld, P; Cavo, M; Usmani, S; Durie, B G M; Avet-Loiseau, H.
Afiliación
  • Chng WJ; 1] Department of Haematology Oncology, National University Cancer Institute, Singapore, National University Health System, Singapore, Singapore [2] Experimental Therapeutics, Cancer Science Institute of Singapore, Singapore, Singapore [3] Department of Medicine, Yoo Loo Lin School of Medicine, Natio
  • Dispenzieri A; Division of Hematology, Mayo Clinic, Rochester, MN, USA.
  • Chim CS; Division of Hematology and Medical Oncology, Queen Mary Hospital, Hong, Kong.
  • Fonseca R; Division of Hematology-Oncology, Mayo Clinic, Scottsdale, AZ, USA.
  • Goldschmidt H; University of Heidelberg, Heidelberg, Germany.
  • Lentzsch S; Department of Medicine, Hematology/Oncology, Columbia University, NY, USA.
  • Munshi N; Dana- Farber Cancer Institute, Boston, MA, USA.
  • Palumbo A; Myeloma Unit, Division of Hematology, University of Torino, Torino, Italy.
  • Miguel JS; Servicio de Hematologia, Hospital Universitario de Salamanca, CIC, IBMCC (USAL-CSIC), Salamanca, Spain.
  • Sonneveld P; Department of Hematology, Erasmus University Medical Center, Rotterdam, The Netherlands.
  • Cavo M; Institute of Hematology and Medical Oncology "Seragnoli", Bologna University School of Medicine, Bologna, Italy.
  • Usmani S; Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
  • Durie BG; Southwest Oncology Group, International Myeloma Foundation, Cedars- Sinai Outpatient Cancer Center at the Samuel Oschin Comprehensive Cancer, Institute, Los Angeles, CA, USA.
  • Avet-Loiseau H; Unité de Génomique du Myélome, University Hospital, Toulouse, France.
Leukemia ; 28(2): 269-77, 2014 Feb.
Article en En | MEDLINE | ID: mdl-23974982
Multiple myeloma is characterized by underlying clinical and biological heterogeneity, which translates to variable response to treatment and outcome. With the recent increase in treatment armamentarium and the projected further increase in approved therapeutic agents in the coming years, the issue of having some mechanism to dissect this heterogeneity and rationally apply treatment is coming to the fore. A number of robustly validated prognostic markers have been identified and the use of these markers in stratifying patients into different risk groups has been proposed. In this consensus statement, the International Myeloma Working Group propose well-defined and easily applicable risk categories based on current available information and suggests the use of this set of prognostic factors as gold standards in all clinical trials and form the basis of subsequent development of more complex prognostic system or better prognostic factors. At the same time, these risk categories serve as a framework to rationalize the use of therapies.
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Mieloma Múltiple Tipo de estudio: Etiology_studies / Guideline / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Leukemia Asunto de la revista: HEMATOLOGIA / NEOPLASIAS Año: 2014 Tipo del documento: Article Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Mieloma Múltiple Tipo de estudio: Etiology_studies / Guideline / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Leukemia Asunto de la revista: HEMATOLOGIA / NEOPLASIAS Año: 2014 Tipo del documento: Article Pais de publicación: Reino Unido